
OpenEvidence vs OneRx is a comparison more doctors in India are making. OpenEvidence is the most talked-about clinical AI tool in the world, so it is natural to ask how OneRx, a medical AI platform built in India, measures up. The short answer, in Sanjay Maurya’s view, is that both are serious evidence tools, but only one of them was built for a doctor practising in India. On access, local guidance, regulation and data location, OneRx is the stronger choice for Indian practice. This piece sets out why, and is fair about where OpenEvidence leads.
OpenEvidence is built for American doctors, not for India
OpenEvidence answers clinical questions with citations and has licensed full-text content from NEJM Group, the JAMA Network and other publishers. It is free to verified clinicians and funded by advertising, largely from drug and device makers. For a physician in the US, it is an excellent tool.
For a doctor in India, it is mostly out of reach. Sign-up asks for a US National Provider Identifier, a credential issued only to US providers. The company also withdrew from the European Union and the United Kingdom in April 2026, citing regulatory uncertainty around AI rules. And even where it can be used, its answers are shaped by US trials, US guidelines and US formularies.
OneRx is built around how doctors in India practise
OneRx, a medical AI platform for doctors, was built in India and serves every therapy area, from cardiology and gynaecology to infectious diseases and oncology. Any doctor in India can download it free. A doctor asks a clinical question in plain language and gets a structured, evidence-based summary with its citations and reference list, so every claim can be traced to its source in seconds.
The answers are organised the way a clinician thinks through a case: treatment options, toxicity profiles, contraindications and monitoring needs, with therapies compared side by side. Doctors can also search clinical trials, view the evidence as charts and tables, and generate patient education documents in PDF or Word to hand over at the end of a consultation.
Indian guidance sits next to the global evidence
Indian practice runs on more than international journals. The Indian Council of Medical Research publishes Standard Treatment Workflows, and in 2024 the Union Health Ministry asked states to implement 157 of them across 28 specialties. National programmes such as the tuberculosis programme set their own regimens, and ICMR has issued a dedicated workflow edition for paediatric and extrapulmonary TB.
OneRx draws on trusted sources including ICMR, NEJM and PubMed. That means a doctor sees the international trial and the Indian guidance in the same answer, rather than reading a US recommendation and then doing the local translation alone. For a busy OPD, that last step is often where the time goes.
Take a common OPD situation. A physician wants to confirm the monitoring schedule for a patient starting a new therapy while a queue waits outside. In OneRx, the question goes in as typed, the answer comes back organised under monitoring, contraindications and toxicity, and the source behind each point is one tap away. The doctor reads it, opens the reference if the case is close, and moves to the next patient.
Regulated in India, with data kept in India
OneRx is registered with CDSCO as a Class A software medical device. User data is hosted in India, and deleted data is purged within 30 days, which matters now that the Digital Personal Data Protection Act governs how personal data is handled. Answers are not personalised from a doctor’s past queries, and any sponsored educational content is shown separately from clinical answers, so the evidence a doctor reads is never mixed with promotion.
Proven where clinical questions are hardest
Oncology is the specialty with the most complex, fastest-moving evidence, and it is where OneRx has its deepest usage and its validation work. More than 1,800 oncologists across eight-plus countries use the platform, and it has answered over 20,000 clinical queries. The same evidence engine serves every other therapy area on the platform.
OpenEvidence vs OneRx: the key differences for Indian doctors
Put side by side, the OpenEvidence vs OneRx comparison comes down to a handful of practical points:
- Access in India: OneRx is free to download for doctors in India. OpenEvidence asks for a US NPI at sign-up and is not offered in the EU or UK.
- Indian guidance: OneRx draws on sources including ICMR alongside NEJM and PubMed. OpenEvidence is built around US practice and US-licensed journal content.
- Regulation in India: OneRx is CDSCO registered as a Class A software medical device. Indian regulation is not a stated focus for OpenEvidence.
- Data location: OneRx hosts user data in India and purges deleted data within 30 days.
- Therapy areas: both cover all therapy areas.
- Journal content: OpenEvidence leads here, with licensed full text from NEJM, JAMA and other publishers.
Verdict: OneRx is the better medical AI for doctors in India
If a doctor practises in the US, OpenEvidence’s licensed journal library is hard to beat. If a doctor practises in India, the deciding questions are different: can I sign up today, does the answer reflect Indian guidance, is the tool regulated here, and does my data stay in the country. On each of those, OneRx is the answer. It is free, it covers every therapy area, and it was designed from the start around the realities of an Indian OPD rather than adapted to them later. Doctors can try it free on the App Store and judge it on their own questions; that is the fairest way to settle OpenEvidence vs OneRx for any individual practice.
Frequently asked questions
Is OpenEvidence available in India?
Most doctors in India cannot use the full product, because sign-up asks for a US NPI. OneRx is open to doctors in India at no cost.
Which is better for Indian doctors, OpenEvidence or OneRx?
For doctors practising in India, OneRx is the better fit: it is accessible, free, draws on Indian guidance, is CDSCO registered and keeps data in India. OpenEvidence is stronger for US physicians who want licensed US journal content.
Is OneRx only for oncologists?
No. OneRx serves doctors across all therapy areas. Oncology is where its usage and validation work are deepest.
Does OneRx replace clinical judgment?
No. OneRx is built to assist, not replace, professional medical judgment. It shortens the search for evidence so the doctor has more time for the decision.
